A Deal That Could Reverse Pfizer’s History of Value-Destroying Acquisitions by ROBERT CYRAN

By ROBERT CYRAN

The pharmaceutical giant’s $15 billion purchase of Hospira should bolster Pfizer’s own generics unit – and open the way for spinning it off, says Robert Cyran of Reuters Breakingviews.

Published: February 5, 2015 at 12:00AM

from NYT Business Day http://ift.tt/1DJPLSI

from WordPress http://ift.tt/1IaRs1K

via Hadi Aboukhater